Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LecB, also known as PA-IIL, is a fucose-binding lectin produced by the opportunistic pathogen Pseudomonas aeruginosa [2, 7]. It is a tetrameric protein that serves as a critical virulence factor by mediating bacterial adhesion to host tissues and facilitating the formation of biofilms [3, 6]. LecB binds to fucose-containing glycoconjugates on host cell surfaces, leading to the internalization of receptors such as integrins, which can impair wound healing and host immune responses [4, 9]. Within the bacterium, LecB interacts with the outer membrane protein OprF to ensure its proper surface localization [3]. Due to its essential role in chronic infections, particularly in the respiratory tract of cystic fibrosis patients, LecB is a prominent target for anti-virulence therapies [2, 16]. Experimental treatments involve the use of glycomimetics and fucose derivatives that competitively inhibit LecB binding, thereby reducing bacterial colonization and increasing the susceptibility of biofilms to antibiotics [2, 3, 16].
Competitive inhibition of carbohydrate-binding sites to prevent bacterial adhesion and biofilm formation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fucose-binding lectin (LecB) (LecB).